175 related articles for article (PubMed ID: 15292227)
1. Molecular mapping of the thrombin-heparin cofactor II complex.
Fortenberry YM; Whinna HC; Gentry HR; Myles T; Leung LL; Church FC
J Biol Chem; 2004 Oct; 279(41):43237-44. PubMed ID: 15292227
[TBL] [Abstract][Full Text] [Related]
2. Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition.
Mitchell JW; Church FC
J Biol Chem; 2002 May; 277(22):19823-30. PubMed ID: 11856753
[TBL] [Abstract][Full Text] [Related]
3. The preferred pathway of glycosaminoglycan-accelerated inactivation of thrombin by heparin cofactor II.
Verhamme IM; Bock PE; Jackson CM
J Biol Chem; 2004 Mar; 279(11):9785-95. PubMed ID: 14701814
[TBL] [Abstract][Full Text] [Related]
4. Role of thrombin anion-binding exosite-I in the formation of thrombin-serpin complexes.
Myles T; Church FC; Whinna HC; Monard D; Stone SR
J Biol Chem; 1998 Nov; 273(47):31203-8. PubMed ID: 9813026
[TBL] [Abstract][Full Text] [Related]
5. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
Sheehan JP; Tollefsen DM; Sadler JE
J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II.
Cooper ST; Rezaie AR; Esmon CT; Church FC
Thromb Res; 2002 Jul; 107(1-2):67-73. PubMed ID: 12413592
[TBL] [Abstract][Full Text] [Related]
7. Arginine 200 of heparin cofactor II promotes intramolecular interactions of the acidic domain. Implication for thrombin inhibition.
Ciaccia AV; Monroe DM; Church FC
J Biol Chem; 1997 May; 272(22):14074-9. PubMed ID: 9162031
[TBL] [Abstract][Full Text] [Related]
8. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.
Van Deerlin VM; Tollefsen DM
J Biol Chem; 1991 Oct; 266(30):20223-31. PubMed ID: 1939083
[TBL] [Abstract][Full Text] [Related]
9. The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.
Boyle AJ; Roddick LA; Bhakta V; Lambourne MD; Junop MS; Liaw PC; Weitz JI; Sheffield WP
BMC Biochem; 2013 Mar; 14():6. PubMed ID: 23496873
[TBL] [Abstract][Full Text] [Related]
10. Site-directed mutagenesis of arginine 103 and lysine 185 in the proposed glycosaminoglycan-binding site of heparin cofactor II.
Blinder MA; Tollefsen DM
J Biol Chem; 1990 Jan; 265(1):286-91. PubMed ID: 2104620
[TBL] [Abstract][Full Text] [Related]
11. Comparison of heparin- and dermatan sulfate-mediated catalysis of thrombin inactivation by heparin cofactor II.
Liaw PC; Austin RC; Fredenburgh JC; Stafford AR; Weitz JI
J Biol Chem; 1999 Sep; 274(39):27597-604. PubMed ID: 10488098
[TBL] [Abstract][Full Text] [Related]
12. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity.
Sheehan JP; Wu Q; Tollefsen DM; Sadler JE
J Biol Chem; 1993 Feb; 268(5):3639-45. PubMed ID: 8429040
[TBL] [Abstract][Full Text] [Related]
13. The interaction of glycosaminoglycans with heparin cofactor II.
Tollefsen DM
Ann N Y Acad Sci; 1994 Apr; 714():21-31. PubMed ID: 8017769
[TBL] [Abstract][Full Text] [Related]
14. Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin.
Holland CA; Henry AT; Whinna HC; Church FC
FEBS Lett; 2000 Nov; 484(2):87-91. PubMed ID: 11068038
[TBL] [Abstract][Full Text] [Related]
15. Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli.
Sarilla S; Habib SY; Tollefsen DM; Friedman DB; Arnett DR; Verhamme IM
Anal Biochem; 2010 Nov; 406(2):166-75. PubMed ID: 20670608
[TBL] [Abstract][Full Text] [Related]
16. Reformable intramolecular cross-linking of the N-terminal domain of heparin cofactor II: effects on enzyme inhibition.
Brinkmeyer S; Eckert R; Ragg H
Eur J Biochem; 2004 Nov; 271(21):4275-83. PubMed ID: 15511233
[TBL] [Abstract][Full Text] [Related]
17. The interaction of glycosaminoglycans with heparin cofactor II: structure and activity of a high-affinity dermatan sulfate hexasaccharide.
Tollefsen DM
Adv Exp Med Biol; 1992; 313():167-76. PubMed ID: 1442260
[TBL] [Abstract][Full Text] [Related]
18. Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II.
Sarilla S; Habib SY; Kravtsov DV; Matafonov A; Gailani D; Verhamme IM
J Biol Chem; 2010 Mar; 285(11):8278-89. PubMed ID: 20053992
[TBL] [Abstract][Full Text] [Related]
19. Functional mapping of the surface residues of human thrombin.
Tsiang M; Jain AK; Dunn KE; Rojas ME; Leung LL; Gibbs CS
J Biol Chem; 1995 Jul; 270(28):16854-63. PubMed ID: 7622501
[TBL] [Abstract][Full Text] [Related]
20. Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex.
Verhamme IM
Anal Biochem; 2012 Feb; 421(2):489-98. PubMed ID: 22206940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]